Bilcare Limited (BOM:526853)
56.18
-1.82 (-3.14%)
At close: Jun 18, 2026
Bilcare Revenue
In the fiscal year ending March 31, 2026, Bilcare had annual revenue of 7.34B INR, down -6.92%. Bilcare had revenue of 1.88B in the quarter ending March 31, 2026, a decrease of -3.28%.
Revenue
7.34B
Revenue Growth
-6.92%
P/S Ratio
0.18
Revenue / Employee
94.04M
Employees
78
Market Cap
1.32B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 7.34B | -544.96M | -6.92% |
| Mar 31, 2025 | 7.88B | 408.57M | 5.47% |
| Mar 31, 2024 | 7.47B | -2.34B | -23.88% |
| Mar 31, 2023 | 9.82B | 1.37B | 16.21% |
| Mar 31, 2022 | 8.45B | 2.22B | 35.65% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bal Pharma | 3.12B |
| Parnax Lab | 2.49B |
| Lactose (India) | 1.63B |
| Aayush Wellness | 1.55B |
| Oxygenta Pharmaceutical | 1.13B |
| Accretion Pharmaceuticals | 898.18M |
| Coral Laboratories | 859.00M |
| Concord Drugs | 787.37M |